Esperion Therapeutics, Inc. - Laporan Laba Rugi (TTM)

Esperion Therapeutics, Inc.
US ˙ NasdaqGM ˙ US29664W1053

Laporan Laba Rugi (TTM)

Laporan Laba Rugi Esperion Therapeutics, Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 219 228 234 62 73 78 89 67 72 75 81 88 103 116 230 278 295 332 260 268
Change (%) 3.95 2.70 -73.42 17.03 7.93 13.84 -24.43 6.77 4.74 7.28 8.58 17.05 13.05 97.48 20.91 6.36 12.48 -21.89 3.29
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 144 149 144 136 131 120 122 137 141 146 157 145 137 129 110 108 107 115 135 144
Change (%) 3.76 -3.34 -5.90 -3.44 -8.36 1.42 12.09 3.48 3.18 7.94 -8.08 -5.10 -5.82 -15.12 -1.65 -0.54 6.90 17.95 6.43
% of Revenue 65.75 65.63 61.76 218.69 180.44 153.21 136.50 202.46 196.22 193.30 194.50 164.66 133.50 111.21 47.80 38.88 36.36 34.56 52.18 53.77
Gross Operating Profit 75 78 89 -74 -58 -42 -33 -69 -69 -70 -77 -57 -34 -13 120 170 188 217 124 124
Change (%) 4.32 14.23 -182.50 -20.68 -28.60 -21.92 112.15 0.27 1.56 8.66 -25.70 -39.36 -62.17 -1,019.64 41.58 10.74 15.66 -42.93 -0.13
% of Revenue 34.25 34.37 38.24 -118.69 -80.44 -53.21 -36.50 -102.46 -96.22 -93.30 -94.50 -64.66 -33.50 -11.21 52.20 61.12 63.64 65.44 47.82 46.23
SG&A 160 200 206 218 195 172 154 124 123 109 109 113 121 143 155 165 172 163 164 159
Change (%) 24.94 3.14 5.77 -10.48 -11.91 -10.15 -19.42 -0.85 -11.52 -0.44 4.01 7.34 17.56 8.48 6.61 4.09 -4.95 0.62 -2.85
% of Revenue 72.99 87.72 88.10 350.62 268.22 218.92 172.78 184.25 171.09 144.53 134.13 128.48 117.82 122.51 67.30 59.34 58.07 49.07 63.21 59.45
R&D
Change (%)
% of Revenue
OpEx 304 349 350 354 326 292 276 261 265 255 266 258 259 272 264 273 279 278 300 304
Change (%) 14.90 0.36 0.96 -7.77 -10.48 -5.39 -5.51 1.42 -3.66 4.36 -3.15 0.35 5.14 -2.75 3.18 2.26 -0.39 7.78 1.35
% of Revenue 138.74 153.35 149.86 569.31 448.66 372.13 309.28 386.70 367.31 337.83 328.63 293.14 251.32 233.72 115.10 98.22 94.43 83.63 115.40 113.22
Operating Income -85 -121 -117 -291 -253 -213 -187 -193 -193 -180 -185 -170 -156 -156 -35 5 16 54 -40 -35
Change (%) 43.17 -4.01 150.14 -13.06 -15.76 -12.45 3.53 -0.45 -6.81 3.13 -8.27 -8.30 -0.09 -77.70 -114.26 232.56 230.61 -173.46 -11.30
% of Revenue -38.74 -53.35 -49.86 -469.31 -348.66 -272.13 -209.28 -286.70 -267.31 -237.83 -228.63 -193.14 -151.32 -133.72 -15.10 1.78 5.57 16.37 -15.40 -13.22
Interest Expense -18 -23 -27 -33 -42 -46 -52 -55 -56 -57 -57 -57 -58 -59 -59 -58 -58 -59 -65 -71
Change (%) 26.91 17.44 24.43 26.34 10.75 12.81 5.97 0.90 1.61 0.57 0.47 1.47 1.25 -0.62 -1.39 0.15 2.36 9.13 10.46
% of Revenue -8.16 -9.96 -11.39 -53.34 -57.58 -59.09 -58.55 -82.11 -77.59 -75.27 -70.56 -65.30 -56.61 -50.70 -25.51 -20.81 -19.59 -17.83 -24.91 -26.64
Net Income -101 -144 -156 -325 -308 -269 -235 -258 -243 -234 -239 -222 -208 -209 -87 -98 -87 -52 -153 -104
Change (%) 42.10 8.84 107.71 -4.95 -12.76 -12.71 9.64 -5.54 -3.96 2.13 -6.87 -6.24 0.41 -58.66 13.86 -11.90 -40.37 196.11 -32.11
% of Revenue -46.15 -63.09 -66.86 -522.50 -424.39 -343.04 -263.04 -381.64 -337.63 -309.58 -294.74 -252.82 -202.51 -179.87 -37.65 -35.46 -29.37 -15.57 -59.03 -38.80

Source: Capital IQ

Other Listings
GB:0IIM
DE:0ET € 2.12
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista